I'll research WST before writing the preview. Let me gather recent earnings materials, guidance, news, and price action.Let me read the most recent quarter's transcript and release, plus the recent 8-K and price action.Let me get the Daikyo 8-K detail and check for analyst expectations/recent news.I have what I need. Here's the earnings preview.
Reports: Thursday, July 23, 2026 (2026Q2 Earnings Call, 8:00 a.m. ET) · Recent price: ~$358 (7/22/26)
WST heads into this print riding one of its strongest stretches in years. The stock closed 7/22 at ~$358, up roughly 30% year-to-date (from ~$276 in early January) and up ~16% just since the Q1 blowout on 4/23 (shares jumped ~13% the day of that report and kept climbing to a fresh high near $366 in early July). At the midpoint of full-year guidance (~$8.57 adjusted EPS), the stock trades around ~42x forward earnings — a premium multiple that leaves little room for disappointment and raises the bar on both the print and any guidance revision.
The bar is high for a reason: management delivered a 45% beat versus the midpoint of its own Q1 EPS guide, and the company has topped Street EPS estimates for four straight quarters. Expectations are now that West keeps the momentum going.
After Q1, West lifted FY26 guidance to revenue of $3.295–3.350B (organic 7–9%, back to its long-term construct from a prior 5–7%) and adjusted EPS of $8.40–8.75 (from $7.85–8.20). Key question for the call: does West raise again? Management explicitly framed the guide as "prudent" with three quarters to go, and the year is now more first-half-weighted than usual — partly by design (see West Vantage below). Any FY raise, especially on EPS, would be the headline.
1. HVP Components — the growth engine (48% of sales). This grew ~23% organic in Q1 and is guided to low-to-mid-teens organic for the year (~7 pts of total company growth). Watch the split: - GLP-1 components (~10% of total sales): guided mid-to-high-teens growth. Management's thesis is that oral GLP-1s expand the market rather than cannibalize injectables. Any commentary on order patterns, oral adoption, ex-U.S. generic launches, and destocking risk is the single most scrutinized data point. - Non-GLP-1 components: the standout in Q1 (high-teens growth, biologics +26%), and management said non-GLP-1 drove two-thirds of the outperformance. Look for confirmation this durable, "boring" growth is sustaining — it's what de-risks the GLP-1 narrative.
2. Annex 1 / HVP conversion. Up 66% y/y in Q1 and framed as a ~200 bps multi-year revenue tailwind, targeting a ~6 billion-unit conversion opportunity. The upside optionality is geographic expansion beyond Europe — management flagged growing FDA/sterility-driven interest in the U.S. and Asia, plus onshoring-driven standardization. Watch for any sign this is broadening.
3. Margins. Adjusted operating margin was 21.4% in Q1 (+350 bps y/y), helped by favorable mix (NovaPure, biologics) and operational-excellence gains at European HVP plants (Eschweiler/Waterford) now being transferred to U.S. sites (Kinston, Jersey Shore). Management guided Q2 margins roughly flat vs. Q1 (~21.4%) with a meaningful second-half step-up, and ~+50 bps to the full-year vs. the prior guide. Offset to watch: higher oil/commodity/logistics costs, which West expects to net to only "single-digit millions" after mitigation (hedging, pricing). Any erosion of the mitigation story matters.
4. SmartDose 3.5mL divestiture to AbbVie. Guidance assumes a mid-year close. Confirmation (or slippage) is a discrete catalyst. Recall SmartDose 3.5 pulled forward revenue in Q1 "in anticipation of the transaction," so watch for a related step-down and clean commentary on the organic bridge. (SmartDose 3.5 generated $55M in 2H25, excluded from organic comps.)
5. West Vantage (renamed CDMO segment, 18% of sales). Grew 6.2% organic in Q1. Guidance is roughly flat for the year, front-half-loaded because of a ~$40M second-half headwind from the rolling-off CGM contract (Q3 expected to be the trough). Offsetting is the higher-margin drug-handling ramp at the new Dublin site (~$20M this year, mostly 2H; management sees ~3x that at peak in 2027 at ~2x current gross margin). Watch the Dublin backfill and drug-handling traction.
6. CEO succession — the wildcard. On the Q1 call, Chairman/President/CEO Eric Green confirmed he is retiring, with a successor expected to be named in 2H26. An announcement could come on or around this call and is a real swing factor for a stock priced for continued flawless execution.
7. Capital returns. The board authorized a new $1B buyback in Q1; West repurchased $298M (1.2M shares at ~$244) in Q1 alone and ended the quarter with $521M cash and a lightly levered balance sheet ($203M long-term debt). Expect continued opportunistic repurchases — though buying near all-time highs is less accretive than the Q1 buying was.
8. Daikyo agreements renewed (7/14/26). West and its 49%-owned affiliate Daikyo Seiko renewed their cross-license and two distributorship agreements on substantially similar terms for a 10-year term. This is a quiet de-risker for the Crystal Zenith franchise and West's exclusive ex-Japan distribution rights — not a needle-mover for the quarter but removes a structural overhang.
The fundamental story is firing on all cylinders — HVP mix shift, biologics/NovaPure, Annex 1, and operational leverage — and estimates sit comfortably within guidance. The risk is almost entirely in expectations and valuation: at ~42x forward EPS near all-time highs, an in-line Q2 with a modest FY raise may already be priced in. The most likely stock-moving items are (1) the magnitude of any full-year guidance raise, (2) GLP-1 order/demand color and destocking risk, (3) the second-half margin ramp holding against commodity costs, and (4) any CEO succession announcement. Given the back-half-weighted guide and management's "prudent" posture, a beat-and-raise is the base case bulls are paying for — anything less than a raise could pressure a richly valued stock.
Note: figures above are drawn from West's Q1 2026 release and earnings call (4/23/26), the 7/14/26 Daikyo 8-K, market pricing through 7/22/26, and publicly reported analyst consensus (~$2.08 EPS / ~$840M revenue). Consensus figures are third-party estimates and may differ from the final tally.